Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Depreciation and Depletion (2016 - 2017)

Bone Biologics has reported Depreciation and Depletion over the past 2 years, most recently at $24.0 for Q4 2017.

  • Quarterly Depreciation and Depletion fell 40.0% to $24.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $96.0 through Dec 2017, down 86.29% year-over-year, with the annual reading at $50.0 for FY2019, 47.92% down from the prior year.
  • Depreciation and Depletion was $24.0 for Q4 2017 at Bone Biologics, roughly flat from $24.0 in the prior quarter.
  • Over five years, Depreciation and Depletion peaked at $580.0 in Q1 2016 and troughed at $24.0 in Q1 2017.